Cancer Clinical Trials: Treatment Costs Associated With a Spanish National Health System Institution
Tóm tắt
Clinical trials should be part of routine health care. There is a common perception that enrolling patients into clinical trials results in additional costs. We conducted a retrospective cost analysis to compare medical costs attributable to participation in cancer treatment trials versus standard of care in a single Spanish institution. Patients recruited into cancer clinical trials between 2014 and 2016 were selected. Each research protocol was reviewed to identify trial-associated medical procedures and costs, as well as the equivalent care had the patient not been entered in the trial. Treatment cost difference was the difference between the cost of the clinical trial and that of the standard of care. A total of 68 adult patients were treated in 20 different clinical trials. The overall cost treatment of the patients included in the trials was 79% lower in comparison to the standard of care. However, the load of medical procedures was 32% higher. The average treatment cost per patient and protocol ranged from an excess of €8193 to a saving of €59,770. There is a wide range of difference in treatment costs for cancer clinical trial participants versus standard of care. Commercial trial protocols were associated with larger savings compared with the noncommercial ones, even though these may involve excess treatment costs. Overall, clinical trials provide not only the best context for progress of clinical research and health care but also creates opportunities for reducing cancer care costs.
Tài liệu tham khảo
Goldman DP, Schoenbaum ML, Potosky AL, et al. Measuring the incremental cost of clinical cancer research. J Clin Oncol. 2001; 19(1):105–110.
Goldman DP, Berry SH, McCabe MS, et al. Incremental treatment costs in National Cancer Institute–sponsored clinical trials. JAMA. 2003;289(22):2970.
Wagner JL, Alberts SR, Sloan JA, et al. Incremental costs of enrolling cancer patients in clinical trials: a population-based study. J Natl Cancer Inst. 1999;91(10):847–853.
Fireman BH, Fehrenbacher L, Gruskin EP, Ray GT. Cost of care for patients in cancer clinical trials. J Natl Cancer Inst. 2000; 92(2):136–142.
Liniker E, Harrison M, Weaver JMJ, et al. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009–2010). Br J Cancer. 2013;109(8):2051–2057.
Real Decreto por el que se regulan los ensayos clínicos con medicamentos, los Comités de Ética de la Investigación con medicamentos y el Registro Español de Estudios Clínicos. RD 1090/2015 [Royal Decree 1090/2015, of 4 December, regulating clinical trials with medicinal products, Ethics Committees for Investigation with medicinal products and the Spanish Clinical Studies Registry].
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Memoria de actividades 2016. Memoria anual de actividades [Spanish Agency of Medicines and Medical Devices. Annual Report of Activities]. 2017:1–144. https://www.aemps.gob.es/laAEMPS/memoria/home.htm. Accessed April 20, 2018.
Tang PA, Hay AE, O’Callaghan CJ, et al. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada. Curr Oncol. 2016;23(suppl 1):S7–S13.
Shen LJ, Chou H, Huang CF, Chou GM, Chan WK, Wu FLL. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan. Contemp Clin Trials. 2011;32(4):485–491.
Mañes-Sevilla M, Romero-Jiménez R, Herranz-Alonso A, et al. Drug cost avoidance in clinical trials of breast cancer [published online ahead of print January 1, 2018]. J Oncol Pharm Pract. doi: 10.1177/1078155218775193.
LaFleur J, Tyler LS, Sharma RR. Economic benefits of investigational drug services at an academic institution. Am J Health Syst Pharm. 2004;61(1):27–32.
Grossi F, Genova C, Gaitan ND, et al. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. Lung Cancer. 2013;81(2):236–240.
Calvin-Lamas M, Portela-Pereira P, Rabuñal-Alvarez MT, Martinez-Breijo S, Martín-Herranz MI, Gómez-Veiga F. Drug cost avoidance in prostate cancer clinical trials. Actas Urológicas Españolas. 2015;39(9):553–557.
Bredin C, Eliasziw M, Syme R. Drug cost avoidance resulting from cancer clinical trials. Contemp Clin Trials. 2010;31(6): 524–529.
García-Pavía P, García Pérez J, García Rodríguez D, González Mirelis J, García Puig J. Cost savings derived from the participation in clinical trials. Rev Clin Esp. 2002;202(2): 66–72.
Izquierdo Alonso J, Fernández Francés J, Almonacid Sánchez C, Gutiérrez Vicente M. Variación del gasto sanitario por la participación de pacientes en ensayos clínicos. Estudio piloto en asma bronquial [Variation in health care costs due to the participation of patients in clinical trials. Pilot study in bronchial asthma]. Rev Patol Respir. 2009;12:13-16.
Resolución 626/2014, de 5 de junio, del Director Gerente del Servicio Navarro de Salud-Osasunbidea, por la que se actualizan las tarifas por los servicios prestados por el Servicio Navarro de Salud-Osasunbidea [Resolution 626/2014, date June 5th, of the Managing Director of the Navarre Health Service, whereby are updated the fees for the services provided by the Navarre Health Service].
McDonagh MS, Miller SA, Naden E. Costs and savings of investigational drug services. Am J Health Syst Pharm. 2000;57(1): 40–43.
Department of Health. Attributing the costs of health and social care Research & Development (AcoRD). 2012:10. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/351182/AcoRD_Guidance_for_publication_May_2012.pdf. Accessed April 20, 2018.